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Abstract
Background: The clinical and histologic appearance of fibrosis in cutaneous lesions in chronic graft-versus -host disease (c-
GVHD) resembles the appearance of fibrosis in scleroderma (SSc). Recent studies identified distinctive structural changes in
the superficial dermal microvasculature and matrix of SSc skin. We compared the dermal microvasculature in human c-
GVHD to SSc to determine if c-GVHD is a suitable model for SSc.
Methodology/Principal Findings: We analyzed skin biopsies of normal controls (n=24), patients with SSc (n=30) and c-
GVHD with dermal fibrosis (n=133)). Immunostaining was employed to identify vessels, vascular smooth muscle, dermal
matrix, and cell proliferation. C-GVHD and SSc had similar dermal matrix composition and vascular smooth muscle
pathology, including intimal hyperplasia. SSc, however, differed significantly from c-GVHD in three ways. First, there were
significantly fewer (p=0.00001) average vessels in SSc biopsies (9.8) when compared with c-GVHD (16.5). Second, in SSc,
endothelial markers were decreased significantly (19/19 and 12/14 for VE cadherin and vWF (p=,0.0001 and ,0.05),
respectively). In contrast, 0/13 c-GVHD biopsies showed loss of staining with canonical endothelial markers. Third, c-GVHD
contained areas of microvascular endothelial proliferation not present in the SSc biopsies.
Conclusions/Significance: The sclerosis associated with c-GVHD appears to resemble wound healing. Focal capillary
proliferation occurs in early c-GVHD. In contrast, loss of canonical endothelial markers and dermal capillaries is seen in SSc,
but not in c-GVHD. The loss of VE cadherin in SSc, in particular, may be related to microvascular rarefaction because VE
cadherin is necessary for angiogenesis. C-GVHD is a suitable model for studying dermal fibrosis but may not be applicable
for studying the microvascular alterations characteristic of SSc.
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Introduction
After allogeneic hematopoietic cell transplantation (HCT), 40–
60% of recipients who survive at least 6 months after HCT will
develop chronic graft-vs.-host disease (c-GVHD) [1]. C-GVHD is
a complex multisystem syndrome with overlapping features of
immunodeficiency and several of the naturally occurring autoim-
mune disorders. A prominent clinical feature of c-GVHD is a
debilitating fibrosing skin disease whose gross and histologic
features resemble both scleroderma (SSc) and, less commonly,
morphea [2,3]. Because of these similarities, a number of murine
models of c-GVHD [4,5] have been used to study the potential
mechanisms underlying SSc. These murine models of c-GVHD
that have produced dermal fibrosis have not successfully
recapitulated the characteristic vascular abnormalities in SSc
including intimal hyperplasia, rarefaction of vessels and pulmo-
nary hypertension [5]. Similarly, other non-GVHD models
including the tight skin mouse and bleomycin induce fibrosis but
do not clearly produce the changes seen in the vasculature of SSc
[6–8].
Data regarding the vascular pathology associated with cutane-
ous c-GVHD are limited. Biedermann [9] et al. investigated the
relationship of superficial dermal microvessels in the papillary
dermis of patients with acute GVHD (a-GVHD) and c-GVHD for
signs of vascular injury and dermal fibrosis. Utilizing staining with
Ulex europaeus agglutinin, they described a loss of superficial dermal
microvessels (a-GVHD less than c-GVHD) accompanied by
perivascular infiltration of activated (GMP17+) CD8+ CD8+ T
cells in skin. Based on these observations, Biedermann et al.
hypothesized that the endothelial cells of the recipient’s superficial
dermal microvessels in cutaneous c-GVHD are targeted by the
alloreactive donor cytotoxic T-lymphocytes leading to blood vessel
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6203loss, impaired blood perfusion, hypoxia, and tissue fibrosis. Other
studies of human intestinal GVHD have emphasized the damaged
capillary bed [10,11], defined as either the presence of apoptotic
cells associated with capillaries, or the presence of thrombotic
microangiopathy.
In our previous investigation of scleroderma (SSc) skin biopsies,
we performed immunohistologic staining with antibodies for
canonical endothelial markers, CD31 (platelet endothelial cell
adhesion molecule), vWF, and VE cadherin. As early as 3 months
after the initial diagnosis of SSc, we found rarefaction of small
vessels [12] and loss of these markers. Because VE cadherin is
essential for tube formation in developing blood vessels [13], we
described the loss of microvessels with the loss of these markers in
the remaining cells as an ‘‘anti-angiogenic’’ phenotype.
In the present study, we compared skin biopsies from patients
with cutaneous fibrotic c-GVHD, SSc, and normal controls. We
evaluated changes characteristic of the vasculopathy of scleroder-
ma including diffuse intimal hyperplasia, endothelial phenotype
and capillary rarefaction [14,15]. Dermal matrix characteristics
were evaluated with hyaluronan staining and graded by a dermal
fibrosis scoring system (DFS) which we have used in a previous
publication [16].
The results showed that c-GVHD lacks some of the distinctive
changes we have previously described in scleroderma.
Results
Dermal fibrosis and other histological features of skin in
SSC and c-GVHD
C-GVHD. The methods used to score DFS are shown in
Table 1. C-GVHD: The clinical and histologic features of the skin
from 13 biopsies with c-GVHD are described in Table 2. Skin
biopsies 1 and 2 in table 2 were on different dates and locations
from the same patient. All 12 patients satisfied the NIH clinical
and histologic consensus criteria for c-GVHD [1,3]. Skin biopsies
were obtained at a median of 642 (range, 320–1323) days after
HCT. Nine of the 13 biopsies had fibrosis with grade 3 or higher
DFS score. The fibrosis involved 50–75% of the dermis, and the
average DFS score was 3.15 for the c-GVHD biopsies. Four of the
biopsies had morpheic clinical and histologic features. The c-
GVHD group displayed the histologic spectrum of c-GVHD from
a lichen planus -like lesions (lichenoid in the NIH classification)
with epidermal acanthosis, hyperkeratosis and hypergranulosis,
intense inflammation along the dermal epidermal junction with
limited fibrosis, to diffuse end-stage fibrotic disease with DFS 4
and 5. With the exception of c-GVHD skin biopsy 2 with
morphea-like disease involving the deep dermis, all c-GVHD
biopsies had fibrotic disease involving at least the upper dermis.
Earlier stages of c- GVHD with lichenoid appearance had
prominent apoptosis along the basilar layers of the epidermis
and follicular and dermal appendages.
SSc. All SSc patients had clinical evidence of diffuse
cutaneous skin fibrosis. Biopsies were primarily from areas of
severe dermal involvement such as the forearm. In contrast to the
skin biopsies from the c-GVHD group, the SSc biopsies had
limited inflammation and little or no epidermal apoptosis. The
extent of fibrosis was histologically comparable to the c-GVHD
biopsies, and the SSc skin biopsies scored a median DFS of 3.
Biopsies from c-GVHD patients with severe fibrotic disease were
indistinguishable histologically from biopsies of patients with
untreated and severe SSc.
Fibrotic changes in SSc and c-GVHD
Compared with normal skin (Figure 1A), the dermal collagen
bundles were replaced by a dense waxy fibrotic matrix in both SSc
(Figure 1B) and c-GVHD (Figure 1 C, D and E). The progression
of the dermal fibrosis in patients with c-GVHD proceeded from
the epidermis down [17]. In contrast, the skin biopsies from some
of the SSc cohort had relative preservation of the dermal collagen
bundles in the upper half of the dermis, while the lower dermis was
intensely fibrotic.
There was increased staining for hyaluronan within the
epidermis and dermis of biopsies from both SSc and c-GVHD.
The elevated level of hyaluronan was especially concentrated
around blood vessels and contrasted with the minimal or absent
staining in the normal control biopsies (shown in supplemental
Figure S1). The hyaluronan stain in the epidermis was also
markedly increased in both fibrotic diseases compared with
normal control biopsies (data not shown).
Intimal hyperplasia in SSc and c-GVHD
The arterial microvessels of SSc displayed mural thickening
including medial smooth muscle hyperplasia and intimal cell
hyperplasia. Hyaluronan staining identified abnormally thickened
vessels since this marker accumulates in intima formed after injury
[18], (Figure 2 A–C). Intimal hyperplasia was present in small and
large vessels of both SSc and c-GVHD and was absent from
normal control biopsies. The elastin layer delimiting the border
between media and intima was often obscured in SSc and the
vessels appeared thickened and abnormal. We stained the biopsies
for smooth muscle actin (SMA) and smooth muscle myosin
(SMMHC) and some of these photomicrographs can be seen in
supplemental Figure S2. We found that there were many more
layers of smooth muscle cells in the arterial walls of the SSc and c-
GHVD skin compared with normal controls (Table 3). We could
not find a difference in the arterial smooth muscle thickness
between c-GVHD and SSc (Table 3). An increase of dermal
myofibroblastic cells were identified by immunostains for the
Table 1. Dermal Fibrosis scoring*.
0 No homogenization but there may be atrophic thin straightened colleen bundles with increased amounts of interstitial ground substance
1 Less than 25% sclerosis with residual foci; some residual straightening or eosinophilic collagen bundles may be present
2 Focal sclerosis – less than 50% overall
3 Incomplete homogenization with spaces between the collagen bundles with 50% to 75% sclerotic change
4 Pandermal sclerosis without obvious expansion of the lower reticular dermis with some sparing of the perieccrine adipose tissue
5 Pandermal sclerosis with homogenization from the papillary to the reticular dermis; includes obvious widening of the reticular dermisbelow the eccrine coils
with extension into the hypodermis and formation of fibrous septa
*DFS was based on H&E stained collagen and dermal matrix changes Blood 2007:110,1388.
doi:10.1371/journal.pone.0006203.t001
CGVHD and SSc Vasculopathy
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GVHD and SSc, respectively (Figure 2 E and F). There was no
difference in myofibroblast numbers between SSc and c-GVHD,
however, both diseases were significantly different from normal
controls (Table 3).
Capillaries are rarefied (reduced) in SSc but not c-GVHD
The results of superficial dermal microvascular vessel density/
hpf are displayed graphically in Figure 3A by triplet sets of bars
representing the quantitations using method 1 as defined in the
materials and methods. Endothelial cells were identified by
antibody staining with CD31, vWF, and VE cadherin. The yellow
colored bars in Figure 3A represent normal controls, the red c-
GVHD, and the multicolored SSc. The error bars represent one
standard error. Average number of vessels for normal skin stained
with CD31 is 17.963 for vWF 14.663 and for VE cadherin
16.263. The average number of vessels in c-GVHD biopsies
stained with CD31, vWF and VE cadherin was 17.863, 18.163,
and 18.364, respectively. The values for each antibody determi-
nation were not significantly different.
The lowest vessel density with each of the three antibodies
occurred in the SSc biopsies. The bar representing average
vessels/hpf was; green CD31 12.262, blue vWF 10.862, purple
VE 9.562. As we reported in a previous study [12], SSc biopsies
showed decreased expression of vWF and VE cadherin when
compared with CD31 (see table 3). Both normal controls and c-
GVHD had significantly more vessels than SSc biopsies when
stained with CD31 (p,0.00001 and p,0.05, respectively) but
there was no difference between c-GVHD and normal biopsies.
Normal controls and c-GVHD tissue stained with antibodies for
vWF had significantly more vessels than SSc biopsies stained with
the same antibody (p,0.05 for both). Again there was no
difference when c-GVHD was compared to normal controls.
Comparing the VE cadherin staining in the three populations,
normal controls or c-GVHD biopsies had significantly higher
vessels/hpf than SSc (p,0.05). VE cadherin staining of normal
versus c-GVHD showed no significant difference. C-GVHD had
the same or slightly more vessels than normal tissue.
Since Biedermann’s paper reported that c-GVHD had fewer
vessels than normal controls using [9], we repeated our vessel
density analysis using Ulex as in their study. We compared 13 c-
GVHD biopsies to 10 normal and 12 SSc biopsies (Figure 3B) In
contrast to the results from Biedermann [9], c-GVHD biopsies
had an average of 20.75 vessels/hpf, slightly increased from
normal controls that had 18.45 vessels/hpf (p=0.12). The SSc
biopsies stained with Ulex differed significantly from both c-
GVHD and normal controls, with an average number of 10.25
vessels per hpf (p,0.00001 for both). In sum, we found that using
Ulex staining the vessel density/hpf in c-GVHD was not decreased,
was approximately the same as the normal controls, and the
counts were very similar to those found using the other three
antibodies.
Endothelial markers are lost in SSc but not c- GVHD
SSc biopsies had a significant reduction of vessels/hpf stained by
vWF and VE cadherin compared with the same biopsies stained
with CD31 (Table 3). Beyond rarefaction, however, our previous
study of SSc reported changes in the phenotype of the
endothelium in the remaining vessels. We confirmed the lack of
vWF and VE cadherin staining in the endothelium of biopsies by
using method 3 (defined in materials and methods) comparing the
photomicrographs of serial section for vessels which were positive
Table 2. Clinical and Histologic Findings in 13 Patients with Chronic GVHD.
Code
Days post
tranplant DFS Score Clinical Findings Histology Comment
GVHD 1 593 5 Morphea pandermal sclerosis, scapular lesion
GVHD 2 623 3 Morphea morphea with deep sclerosis in lower 66% of dermis and
lichenoid activity but without apparent subepidermal sclerosis
GVHD 3 382 3 Tight skin hair loss oral and liver
involvement
Dense sclerosis of upper 33% dermis and sclerosis in deep
retic d.
GVHD 4 810 1 Tight skin with limited range of
motion
lichenoid patchy subepid sclerosis, marked vascular prolif &
inflam
GVHD 5 991 5 Sclerosis with limited range of motion
oral and ocular involvement
pandermal sclerosis
GVHD 6 642 5 Extensive scleroderma oral and ocular
involvement
dense pan dermal sclerosis
GVHD 7 320 1 Extensive lichen planus-like lesions
without sclerosis
lichenoid, mild subepid sclerosis, perivascular inflamation
GVHD 8 618 5 Morphea pan sclerosis
GVHD 9 1323 0–1* Dyspigmentation, tightness, lichenoid
lesions, hair loss
lichenoid, focal subepidermal sclerosis
GVHD 10 1142 3 Prior fasciitis, dyspigmentation,
inactive when biopsied
sclerotic with some residual nl dermis in mid-reticular zone
GVHD 11 437 1 Oral and ocular sicca, skin tightness
with rash and deep sclerosis
lichenoid, thin band of subepid dermal sclerosis
GVHD 12 1076 4 Lichenoid plaques, fibrosis of the
hands
pan dermal sclerosis, ectatic superficial venules
GVHD 13 985 3 Left flank morphea, poikiloderma with
sclerosis
dense deep reticular dermal and fascial sclerosis. Subepidermal
sclerosis with sparing of upper reticular derma
doi:10.1371/journal.pone.0006203.t002
CGVHD and SSc Vasculopathy
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SSc had vessels that were clearly positive for CD31 while negative
for the other canonical markers (Table 1). Representative
photomicrographs show the endothelial markers in normal skin
and c-GVHD skin are quite visible (Figure 4 A-C) whereas VE
cadherin is missing from vessels in SSc skin (Figure 4 D). Similarly
Ulex europaeus lectin was seen in every vessel stained with CD31
when the biopsies are compared side by side (data not shown). As
we have previously published, SSc has not only lost vessels, the
remaining vessels are only sometimes positive for Ulex.
Focal areas of capillary proliferation with increased
endothelial markers are identified c- GVHD
The term lichenoid defined by the NIH consensus criteria for c-
GVHD refers to the early cutaneous histologic changes where
there is epidermal orthokeratosis, hypergranulosis, acanthosis, and
extensive inflammation with apoptosis along the basal layer with
damage to the rete ridges [3]. In the course of our vessel studies we
noted that some c-GVHD biopsies, especially those with a
lichenoid histologic picture, had areas of microvascular prolifer-
ation in the papillary dermis that were not present in normal
controls. The structure of these clusters of cells resembled
glomeruloid bodies [19]. The cells in these structures were positive
for endothelial markers (Figure 5 A and B). A few SSc biopsies had
similar structures, however, the endothelial cell markers were
sparse within them (Figure 5 C and D). In both SSc and c-GVHD
there were cells in these structures positive for Ki67 implying that
glomeruloid bodies represent proliferative structures. Additional
photos of the proliferative areas in c-GVHD and SSc are available
in supplemental Figure S3.
Discussion
In spite of similarities in cutaneous fibrosis, the clinical
presentation of c-GVHD differs from SSc in several ways
including the absence of Raynaud’s phenomenon, a general lack
Figure 1. Dermal fibrosis in skin biopsies of Normal, c-GVHD and SSc skin. Normal skin stained A. with H&E has collagen bundles with
curlicue pattern and a dermal fibrosis score (DFS) of zero. 206magnification B. SSc depicting a DFS of 5 at 206magnification. C. GVHD day 810 DFS
1: epidermis has patchy lichenoid lymphocytic inflammation along the dermal epidermal junction the widened and papillary dermis contains loosely
scattered myofibroblasts and clusters of small proliferated vessels (lower power is 106) D. GVHD4 day 382 DFS 3: the entire papillary and upper
portion of the reticular dermis are replaced by dense fibrosis in a the top-down direction E. GVHD8 day 642 DFS 5: Fibrotic disease throughout the
dermis with replacement of the loose papillary dermal collagen and reticular dermal collagen bundles by dense smudgy collagen.
doi:10.1371/journal.pone.0006203.g001
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autoantibody profile of SSc and internal organ disease as is seen
in diffuse SSc. The observations in this study moreover, show that
the superficial dermal microvessels in c-GVHD differ from those
seen in SSc by having neither capillary rarefaction nor the loss of
endothelial cell specific markers we described before [12]. In fact,
many biopsies of c-GVHD were associated with an increase of
small vessels and in some we found small plexiform microvascular
Figure 2. Myofibroblasts and intimal hyperplasia in Normal, GVHD and SSc skin. Smooth muscle markers were used to depict mural cells
and pericytes. A. Smooth muscle actin (SMA) in normal control with normal positive cells in vessels. B. C-GVHD biopsy with many SMA+
myofibroblasts C. Representative SSc biopsy with SMA+ myofibroblasts in dermis slightly lower than c-GVHD Hyaluronan can be used to show
abnormally thickened vessels since this marker tends to accumulate on intima and in smooth muscle cells after injury. D. Normal skin showing
unaltered vessels in lower dermis. E. C-GVHD biopsy showing thickened vessels with some hyaluronan in the vessel wall. F. Similarly thickened
vessels in SSc with increased hyaluronan.
doi:10.1371/journal.pone.0006203.g002
Table 3. Quantification of Immunohistochemistry scores.
Category Normal SSc cGVHD NL vs. SSc NL vs. cGVHD SSc vs. cGVHD
Average DFS 0–5 0.1 2.7 3.1 ,0.05b ,0.05b nsb
SMA myofibroblasts #positive/#total 0/16 8/11 5/7 ,0.0001a ,0.05a nsa
SMMHC intimal hyperplasia #positive/#total 0/7 10/11 5/6 ,0.05a ,0.05a nsa
SMMHC mypfibroblasts #positive/#total 0/7 8/11 5/6 ,0.05a ,0.05a nsa
Loss of VE Cadherin #positive/#total 0/15 19/19 0/13 ,0.0001a nsa ,0.0001a
Loss of vWF #positive/#total 0/8 12/14 0/13 ,0.05a nsa ,0.05a
ns–not significant.
a–Fisher’s exact test.
b-Mann Whitney test.
doi:10.1371/journal.pone.0006203.t003
CGVHD and SSc Vasculopathy
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These structures resemble capillary malformations resulting from
local overexpression of VEGF [20,21] suggesting that VEGF may
be overexpressed in the skin of c-GVHD patients as it is in the skin
of patients with SSc [22]. This hypothesis is supported by Shimura
et al who reported an increase in circulating levels of VEGF in c-
GVHD [20]. Only one end stage pansclerotic c-GVHD biopsy
showed vascular rarefaction.
Our results disagree with the findings reported by Biedermann
et al. [9]. They claimed loss of capillaries resulted from targeting of
host endothelial cells by alloreactive donor cytotoxic T-cells in c-
GVHD results in loss of the capillaries with subsequent ischemia
and ischemia driven dermal fibrosis. Their hypothesis is consistent
with in vitro studies showing that allogeneic T cells can kill
endothelial cells [23]. Shimura et al. [24] provided support for
Biedermann’s hypothesis. In five patients with sclerodermatous c-
GVHD, Shimura et al. found a reduction in circulating CD34+/
CD133+ putative endothelial precursors when compared to
controls and c-GVHD patients without fibrosis of the skin.
Biedermann et al. inferred endothelial injury by the histologic
appearance of reactive swollen endothelium and the presence of
elevated vWF multimers. Personal experience (HMS) in evaluating
thousands of c-GVHD biopsies as well as observations by
Biedermann et al. over a wide range of times after allotransplan-
Figure 3. Capillary counts in c-GVHD compared with normal controls and SSc. Vessel counts by antibody staining A. show SSc has
significantly fewer vessels than both other patient groups. Yellow bars show normal tissue vessel counts, red bars show c-GVHD vessels counts, and
green blue and purple bars show SSc biopsies stained with CD31, vWF and VE Cadherin respectively. Normal controls and c-GVHD counts are not
significantly different from each other regardless of marker used. These counts are also not significantly different within the group (i.e. CD31 stained
normal tissue has similar number of vessels to normal tissue stained with vWF). SSc has fewer vessels than c-GVHD and normal tissue with every
antibody used to label endothelial cells. In addition, the remaining vessels in SSc (total represented by green bar) a significant proportion of these
vessels have lost expression for vWF (blue bar) and VE Cadherin (purple bar). B. Graph shows the results of vascular density quantification after Ulex
lectin staining. Normal controls and c-GVHD biopsies are represented by the yellow and orange bars, and are not significantly different. Blue bar
represents the average number of vessels in SSc, and is significantly less than the other two groups.
doi:10.1371/journal.pone.0006203.g003
CGVHD and SSc Vasculopathy
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hemorrhage, edema, thrombosis, or endothelial apoptosis.
The disparity between our conclusions with Ulex and the data
from Biedermann et al. may be explained by three differences in
the studies. First, we do not regard elevation of vWF multimers as
evidence of an alloreactive endothelial injury but rather as an
indication of perturbation of the endothelium involved in the
inflammatory process by the homing of alloimmune lymphocytes
and the surrounding cytokine milieu [25,26]. Additionally vWF is
elevated in response to some kinds of drug therapy [27] and is
considered to be a non-specific acute phase reactant in the
inflammatory process [28].
The second difference is the criteria for defining endothelial
cells. Ulex lectin detects glycosylation products of blood group
antigens rather than a protein or RNA expressed by the
endothelial cell. The Ulex antigen is a specific fucose moiety
Figure 4. Only SSc has lost endothelial cell markers. Depicted in A. Normal skin stained with VE cadherin and CD31 showing similar patterns of
staining. The same patterns are seen in B. early c-GVHD stained with the same two antibodies and C. late c-GVHD similarly stained with VE cadherin
and CD31. The only skin samples which showed loss of VE cadherin were the SSc biopsies D.
doi:10.1371/journal.pone.0006203.g004
CGVHD and SSc Vasculopathy
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reports show that fucosylases can compete with each other and
with other transferases especially in the presence of inflammation
[30]. In contrast CD31 is the marker most commonly used to
identify vascular endothelia and VE cadherin is made uniquely by
endothelial cells [31]. The third difference is the morphometric
method used to count vessels. In our study of SSc we saw a specific
loss of small thin walled vessels (dermal capillaries) [12].
Biedermann et al. describe measuring the total surface area
stained by Ulex lectin without regard to vessel size. An examination
of Figure 2 suggests that they may have seen a shift in mean vessel
size rather than numbers. A decrease in total vessel circumference
may simply mean that the vessels are smaller in c-GVHD, which is
consistent with increased numbers of small newly made capillaries.
Although we did not see capillary rarefaction in c-GVHD we
did see intimal hyperplasia, another important vascular pathology.
Both SSc and cGVHD have changes in smooth muscle thickness
in vasculature of the skin. Diffuse intimal hyperplasia similar to
that seen in SSc and c-GVHD is solid organ transplant of heart,
lung, and kidney. Fibrosis accompanies the vascular changes of
transplant arteriosclerosis [32].
Despite the similarities between SSc and c-GVHD there is a
difference in the pattern of fibrotic change. With the exception of
one patient with morphea-like changes in only the lower dermis, c-
GVHD biopsies showed dermal fibrosis proceeding in a top-down
manner, spreading downward from the papillary and adnexal
dermis surrounding destroyed follicles [3]. This is opposite from
the usual pattern in SSc where fibrosis extends from the
hypodermis upward.
The cell usually implicated in fibrosis of SSc is the myofibro-
blast, defined as a fibroblast with abundant expression of smooth
muscle contractile genes [33]. Both SSc and c-GVHD have
spindle-shaped, smooth muscle actin positive myofibroblasts
scattered within the increased matrix.
The molecular stimuli for fibrosis in SSc and c-GVHD may be
similar. Fibrosis is driven by soluble mediators from differentiated
type 2 immune response [34] including Il-4, Il-13 and TGF-
b[35,36]. Experimental data indicate that TGF-b, a potent driver
of fibrosis is involved in both the genesis of c-GVHD [5] and SSc
[37]. In vitro data suggest that myofibroblast formation is driven
by PDGF and TGF b [38,39]. Experimental animal models
enhancing TGF b activation (e.g. by mutations in the TGF b
binding domain of fibrillin) demonstrate severe fibrotic reactions
[40]. Recent studies in mice show the fibrosis is antagonized by
losartan[41]. Svegliati [42,43] has described an autoantibody in
patients with SSc and c-GVHD which reacts with the PDGF
Figure 5. Endothelial markers in clumps of microvascular proliferative formations in GVHD but not SSc. C-GVHD with areas of
microvascular proliferation A. Many VE cadherin positive cells present throughout the structure. Some of the endothelial cells within the structure
have a normal aggregated stain pattern with VE cadherin at the junctions, wheras in proliferating and migrating endothelial cells the VE cadherin is
spread out in the cytoplasm. VE cadherin spread in the cytoplasm is a typical finding in proliferating endothelial cells in glomeruloid bodies in skin. B.
CD31 stained biopsies of c-GVHD with glomeruloid bodies with many cells positive for CD31 appearing in large clumps. Similar appearing structures
in SSc did not have endothelial markers present in the cells. C. SSc, VE cadherin has few weakly positive cells lining the lumens and very few readily
identifiable proliferating endothelial cells D. SSc,CD31 positive cells are sparse in these areas structurally resembling microvascular proliferation.
Although multiple lumens are present there are very few CD31 positive clumps of cells.
doi:10.1371/journal.pone.0006203.g005
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underway that may test the therapeutic implications of this
hypothesis. First, rituxan, an anti CD20 with reactivity against B
cell activity, has been used with some success in treating
obliterative bronchiolitis and skin manifestations of c-GVHD
[44]. Second, a multi-institutional study with imantinib, a tyrosine
kinase inhibitor is directed at shutting down activation of
fibroblasts by blocking PDGF signaling.
In summary, while c-GVHD and SSc may share common
fibrotic mechanisms, our data suggest that rarefaction and loss of
endothelial-specific markers may be specific to SSc and offer a
clinical target in its own right. Recent clinical trials using
autologous HCT for severe SSc showed arrest or reversal of
dermal fibrosis associated with regeneration of dermal capillaries
and restitution of the endothelial phenotype [12,16]. Clinical trials
of allogeneic grafts into SSc patients are ongoing, and a percentage
of these patients these are expected to develop c-GVHD. Presence
or absence of VE cadherin and vascular density may have utility in
these studies to distinguish c-GVHD from persistent SSc in
allogeneic stem cell transplant recipients. The mechanism for the
regenerative effect of HCT is not yet known, however, it is
intriguing to consider the possibility that the critical result is
endothelial regeneration.
Materials and Methods
Ethics Statement
The investigations in this study were based on skin biopsies
supplied in collaboration and analyzed according to the University
of Washington Institution Review Board approved protocols for
human studies (#29426 and #D3-8439-D 03). The biopsies were
provided by Stanford University, University of California San
Francisco, Boston University, Fred Hutchinson Cancer Research
Center, Seattle Cancer Care Alliance and the University of
Washington Medical Center. Biopsies were selected from stored
tissue that was collected for other studies, de-identified prior to
delivery to our institution for analysis, and written consent was
unnecessary for the specific purpose of this study.
Patients
The biopsies came from 24 normal controls, 30 SSc patients
and 12 c-GVHD patients with patient 1 having two biopsies done
on separate days. Additional details on the normal and SSc
patients are provided on supplemental tables S1 and S2. Clinical
data was available for 22 of 24 normal controls ages range from 36
to 73 with the majority of biopsies from forearm although there
were also samples from scalp and torso. Clinical data was available
for all SSc patients, ages range from 32 to 71 and disease duration
range from 6months to 6 years. Most of the SSc biopsies were
from the forearm, although there were also samples from torso and
thigh. The skin biopsies with c-GVHD were obtained from the
University of Washington affiliated institutions.
Dermal fibrosis score
After reviewing the pathology archive between 2005–2007, we
identified skin biopsies from 13 patients whose biopsies had
subtotal to complete dermal sclerosis and satisfied the NIH
histopathology requirements for c-GVHD [3]. Table 2 shows the
age, day post-transplant and their dermal fibrosis score (DFS) [45]
which reflects the percentage of sclerosis in the full thickness of
dermis with by quintiles; grade 1,25%, grade 2 25–50%, grade
50–75%, grade 4 pandermal sclerosis, grade 5 pandermal sclerosis
with extension into the hypodermis The evaluation of DFS was
done on sections stained with H&E.
Immunohistochemistry (IHC)
In order to comprehensively define the components of the small
vessels the antibodies used were directed at three general
categories; first, endothelium, physiologic antibodies CD 31, VE
cadherin, vWF and the lectin Ulex europeus which stains fucosylated
substances on the endothelium and basement membrane,), second,
vascular smooth muscle (non muscle myosin heavy chain, smooth
muscle myosin heavy chain and smooth muscle actin) and third,
intimal matrix (hyaluronan). Evidence of active cell cycle
proliferation was done with Ki67. The manufacturer, clone,
dilution, and pretreatment details for each primary antibody are
summarized in supplemental Table S3. Immunohistochemistry for
VE cadherin, vWF, smooth muscle myosin heavy chain
(SMMHC) and some a smooth muscle actin (SMA) was performed
at Phenopath Laboratories (Seattle, Washington). Some of the
immunostaining for CD31, some a smooth muscle actin, and some
vWF was performed at the Seattle cancer care alliance pathology
laboratory using similar protocols.
Immunohistochemistry for hyaluronan was done at the Wight
lab: Paraffin sections were dewaxed, endogenous peroxidases were
blocked using H2O2 in methanol, and rehydrated in a series of
graded ethanol. For hyaluronan affinity histochemistry, rehydrat-
ed tissue sections were blocked in 1%BSA-PBS and incubated with
biotinylated hyaluronan binding peptides (4 ug/ml) and hyaluron-
idase treatment of sections was used as a negative control. The
slides were incubated for 30 minutes with the ABC reagent
supplied in Vector Elite Universal Kit (Vector Labs #PK6100).
Detection was performed with Vector NovaRed substrate to create
a red color (Vector Labs # SK-4800), the slides were then
counterstained with Gills #3 Hematoxylin, dehydrated in ethanol
series, cleared in xylene and mounted with Quik-Mount (Research
Products International Corp., Mount Prospect, IL).
IHC Scoring methodology
Quantitative microscopy was done using an Nikon E400
Microscope with a 20x optic, numerical aperture 0.75 with 106
eye pieces.
Myofibroblasts score (SMA, SMMHC). Non-perivascular
cells identified as existing isolated in the matrix (i.e.) not part of a
smooth muscle fiber. Biopsies were considered positive if there
were groups (more than 3) of these scattered cells present. Biopsies
were scanned and presence or absence recorded.
Intimal/Smooth Muscle Vascular Pathology (SMA,
SMMHC). The biopsies were scanned until positive vessels
were located or the entire biopsy had been examined for blood
vessels with greater than 3 layers of smooth muscle in the blood
vessel wall. The range and average number of normal skin vessels
with greater than 3 layers per height per hpf was determined. The
mean was calculated and assuming a normal distribution, biopsies
within two standard deviations of the positive range were scored as
positive. Biopsies with an average number of cells lower than the
cutoff were scored as negative. Negative and positive were
recorded in 262 frequency tables.
For our purposes, superficial dermal vessels were defined as
those vessels within one hpf of the epidermis. All the vessels
(clumps of cells or cells surrounding a lumen that were positive for
the endothelial marker) within one hpf of the epidermis were
counted in four separate sections of the biopsies. This method was
designed to include capillaries and sections of tissue that don’t
include the lumen of the vessel in the cell counts.
Vessel quantification. The quantitative vascular counts
were performed by comparing the four endothelial
immunohistologic stains on serial sections. The quantitation
focused on the papillary dermis located just below the epidermis,
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the dermis. Four contiguous high power fields (hpf) or the entire
breadth of the biopsy was counted. The comparative
photomicrographs of serial sections with different
immunohistologic stains were taken of the upper dermis
extending from just below the epidermis. All quantitations were
done on coded section by at least one blinded observer. If the
vascular quantitation counts from a given biopsy differed
substantially between endothelial stains, the quantitation was
repeated by at least two additional blinded observers to verify the
significant differences using different vascular antibody stains.
Determination of vessel rarefaction
The average vessel counts with the four endothelial marker
antibodies for normal control biopsies were compared to those
counts from c-GVHD and SSc biopsies. Differences expressed
using students t-test statistics are shown in Figure 3.
Loss of endothelial phenotypic markers vWF and VE
cadherin
Loss of vascular staining vWF and VE cadherin was determined
by comparison with the CD31 counts using students t test statistics
(Figure 2.) The loss of endothelial cell VE cadherin and/or vWF
immunoreactivity in SSc biopsies was verified was by comparing
photographs of serial sections stained with VE cadherin and vWF
to the same vessel which displayed immunoreactivity to CD 31.
Positive (for loss) or negative (no loss of staining) was recorded in
2X2 table and statistically analyzed by fishers exact significance
test. Results are shown in Table 1.
Statistics. The stain scores for intimal hyperplasia, vessel
quantification method 3, smooth muscle capillary scores and
myofibroblast scores were recorded as frequency data and were
analyzed for significance using Fishers Exact Significance test or
the Mann Whitney test. Frequency data were obtained according
to above scoring systems and 262 tables were used to record
differences between groups. P values were calculated with one
tailed probability value. The numbers per hpf for the remainder of
the stains and methods 1 and 2 for vessel quantification were
recorded and continuous variables and therefore tested for
significance with the students t test. Two tailed p values were
used to show significance.
Supporting Information
Figure S1 Histochemistry of scleroderma dyregulation of matix
molecules A. Increased hyaluronan is present in Ssc and GVHD in
the A dermal matrix and in B. areas of microvascular
proliferation/cellularity.
Found at: doi:10.1371/journal.pone.0006203.s001 (1.72 MB TIF)
Figure S2 Intimal hyperplasia or smooth muscle hyperplasia in
SSc and c-GVHD A. lichenoid c-GVHD SMMHC antibody
depicts multiple layers of smooth muscle in skin vessels. No such
vessels were found in any of the many full thickness biopsies of
normal controls skin. B. Sclerotic c-GVHD stained with SMA,
shows both larger and smaller vessels with multiple layers of
smooth muscle cells, with scattered myofibroblasts and increased
cellularity highlighting the inflammatory nature of c-GVHD C.
SSC stained with an antibody to SMMHC shows thickened vessel
walls around swollen endothelial layer
Found at: doi:10.1371/journal.pone.0006203.s002 (1.80 MB TIF)
Figure S3 Endothelial markers in clumps of microvascular
proliferative formations in GVHD Sclerotic cGVHD with areas of
microvascular proliferation as defined by A. vWF B. SMA similar
formations were seen in lichenoid cGVHD as defined by E. vWF
and F. SMA similar appearing structures in SSc did not have
endothelial markers present in the cells G. VE cadherin is shown
with H. CD31, positive cells are sparse in these areas, although
multiple lumens are present
Found at: doi:10.1371/journal.pone.0006203.s003 (2.56 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0006203.s004 (0.07 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0006203.s005 (0.06 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0006203.s006 (0.04 MB
DOC)
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